UNSPSC 51132234: Aspirin/caffeine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132234 Aspirin/caffeine/salicylamide is a Commodity code, but the recent state and local opportunities posted under it do not align with the code's nominal scope. The three most recent solicitations cover naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which match aspirin/caffeine/salicylamide formulations. The code shows little relevant recent activity for the product category it nominally describes.

The misclassification appears systematic across issuing bodies. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems through competitive IFB; the Texas Health and Human Services Commission (HHS0017013, posted April 3, 2026) issued an RFI on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, due March 26, 2026) posted an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon. Activity is concentrated in Texas, Florida, and Minnesota, but the underlying procurement is for pharmaceutical supply and distribution infrastructure rather than aspirin-based analgesic formulations. Firms pursuing opportunities under this code should verify UNSPSC classification in actual solicitations, as state and local procurement offices may apply the code inconsistently or to broader pharmaceutical categories than the code's name suggests.